ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

ClinicalTrials.gov ID: NCT05646706

Public ClinicalTrials.gov record NCT05646706. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 4:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity

Study identification

NCT ID
NCT05646706
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
1,407 participants

Conditions and interventions

Conditions

Interventions

  • Placebo Drug
  • Semaglutide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 3, 2023
Primary completion
Oct 29, 2024
Completion
Nov 25, 2024
Last update posted
Apr 22, 2026

2023 – 2024

United States locations

U.S. sites
21
U.S. states
10
U.S. cities
18
Facility City State ZIP Site status
Univ of Alabama Birmingham Birmingham Alabama 35294
Chambliss Clinical Trials, LLC Montgomery Alabama 36106
Healthscan Clinical Trials,LLC. Montgomery Alabama 36106
Diablo Clinical Research, Inc. Walnut Creek California 94598
Jacksonville Ctr For Clin Res Jacksonville Florida 32216
Florida Inst For Clin Res LLC Orlando Florida 32825
Florida Institute For Clinical Research LLC Orlando Florida 32825
East West Med Res Inst Honolulu Hawaii 96814
Midwest Inst For Clin Res Indianapolis Indiana 46260
AMC Community Endocrinology Albany New York 12203
University of North Carolina Chapel Hill North Carolina 27514
PharmQuest Life Sciences LLC Greensboro North Carolina 27408
Medical University Of South Carolina Charleston South Carolina 29425
Amarillo Med Spec LLP Amarillo Texas 79106
Elligo Clin Res Centre Austin Texas 78704
Velocity Clin Res, Dallas Dallas Texas 75230
UT Southwestern Medical Center-CRU Dallas Texas 75390
DCOL Ctr for Clin Res Longview Texas 75605
Sugar Lakes Family Practice PA Sugar Land Texas 77479
National Clin Res Inc. Richmond Virginia 23294
Selma Medical Associates Winchester Virginia 22601-3834

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05646706, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 22, 2026 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05646706 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →